PP
AKBA icon

Paloma Partners’s Akebia Therapeutics AKBA Stock Holding History

Paloma Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-20,000
Closed -$78K – 2116
2019
Q3 		$78K Buy
+20,000
New +$85.7K ﹤0.01% 1857

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's AKBA Position: Q4 2019 in Review

Paloma Partners sold out of Akebia Therapeutics (AKBA) in Q4 2019, closing a stake of 20,000 shares — an estimated $78K sold.

Paloma Partners first reported a position in AKBA in Q3 2019 and held it in 1 quarter. The position peaked at $78K in Q3 2019. 153 funds tracked by Wall St. Rank hold AKBA as of Q4 2019.

  • Paloma Partners reported no remaining Akebia Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Paloma Partners sold 20,000 Akebia Therapeutics shares in Q4 2019, an estimated $78K.
  • Paloma Partners first reported a position in Akebia Therapeutics in Q3 2019 and held it in 1 quarter.
  • Paloma Partners's Akebia Therapeutics position peaked at $78K in Q3 2019.
  • 153 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2019.

Based on Paloma Partners's 13F filing for Q4 2019, filed 14 Feb 2020.